I really appreciate your post.
I appreciate all the carefully constructed opinions and positive posts.
This post is all my opinion and thoughts.
And mine are positive beliefs.
People who have read every RAP article, viewed and given thought to every RAP asx announcement, watched every RAP youtube, viewed all RAP presentations, listened to all RAP investor conference calls and asked questions and have corresponded with RAP management know that RAP is on track and headed for commercialization with CE Mark and TGA for child and most likely adult use as our Australian Adult trial is near completion and these CE and TGA approval will happen before and during the decision making process of FDA approval.
I see the FDA taking into account the use and approval of Resapp based on Australian blind trial and the failure of their own US doctors to fail by over 30% to make a diagnosis.
Use in CE mark countries and great Australian blind trial results will influence FDA .
The bottom line is
Is it safe?
Is it a valuable aide to Dr's in ED and GP practices and during a patient doctor video consultation (Telehealth)?
And the cream on the cake after ticking all the above is "Will the use of Resapp save the health insurers money.
It is the the yes answer to this last question that will have Health Insurers driving the use of Resapp during a telehealth visit over a presentation to a hospital ED or a direct consultation with a doctor.
When Resapp has been used at home during a telehealth consultation and the Dr during the consultation recommends the patient attend a Hospital ED, the patient can also take to the hospital triage nurse, the Telehealth Dr's urgent request and the Resapp diagnosis for the patient to be seen urgently be seen by ED Dr. I will go one further and say the patient will be rushed by ambulance to ED with Dr's request and Resapp diagnosis........if and when...necessary.
Resapp has the potential to save many lives when used as a diagnostic aide during a GP telehealth visit.
The telehealth market in CE mark countries is growing exponentially.
New broad band high speed satellites are being launched into space every month.
Mobile phone and IPad device use is growing exponentially.
I am seeing Australian Adult Clinical blind trial results.
An Announcement on final report on US Smartcough c study
Announcement on Filling CE Mark submission.
CE Mark approval
I have my fill of o.....so cheap RAP shares now.
Carry on.
Happy Bentley
- Forums
- ASX - By Stock
- RAP
- Ann: ResApp Receives Notice of Allowance for Core Patent in Japan
Ann: ResApp Receives Notice of Allowance for Core Patent in Japan, page-68
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
-
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)